세계의 성인용 백신 시장 : 백신, 백신 유형, 기술, 최종 사용자, 지역별(2026-2032년)

Adult Vaccine Market Valuation - 2026-2032

The rising prevalence of infectious diseases such as influenza, hepatitis, and zoster, as well as government programs to raise awareness of the importance of immunization are driving expansion in the adult vaccine market. The global adult vaccine market study offers a comprehensive assessment of the market. The market size surpass USD 17279.87 Million valued in 2024 to reach a valuation of around USD 27750.04 Million by 2032.

In addition to this, the rising increased research into vaccination technologies and growing government funding are enabling the market to grow at a CAGR of 6.10% from 2026 to 2032.

Adult Vaccine Market: Definition/ Overview

Adult vaccines are immunizations designed for individuals aged 18 and older, aimed at preventing infectious diseases and reducing the risk of severe illness, complications, and pathogen transmission. These vaccines can be administered as primary or booster doses to maintain immunity from childhood vaccines.

Some common types of adult vaccines include influenza (Flu), tetanus, diphtheria, and pertussis (Tdap), pneumonia, shingles, human papillomavirus (HPV), hepatitis A and B, measles, mumps, and rubella (MMR), chickenpox, meningococcal, and hepatitis C. Influenza vaccines are recommended annually to protect against seasonal influenza viruses, especially for high-risk groups like older adults, pregnant women, healthcare workers, and individuals with chronic health conditions. Tdap vaccines are given as a booster every 10 years to maintain protection against tetanus, diphtheria, and pertussis.

Pneumococcal vaccines are recommended for adults 65 years and older, as well as younger adults with certain medical conditions, to prevent pneumonia, meningitis, and bloodstream infections caused by Streptococcus pneumoniae bacteria. Herpes zoster vaccines are recommended for adults 50 years and older to prevent shingles, a painful rash caused by the varicella-zoster virus. HPV vaccines are recommended for adults up to age 26 to protect against cervical, anal, and other cancers, as well as genital warts.

Advancements in treatment and prevention strategies, including vaccines for hepatitis A and B, are essential in managing HCV infections and preventing liver-related complications. Vaccination recommendations may vary based on age, health status, occupation, travel history, and other factors, so consulting with healthcare providers or public health authorities is crucial for determining the appropriate vaccine schedule for each individual.

According to the NCBI, vaccine-preventable diseases kill many adults each year in countries such as the United States. Furthermore, according to the Center for Disease Control (CDC), individuals require an influenza vaccine each year since the vaccine is crucial for those with chronic illnesses, the elderly and pregnant women. According to CDC recommendations each adult must be immunized once with the Tdap (Tetanus, Diphtheria, and Pertussis) vaccine to protect against whooping cough if they have not already been immunized. Adults are also given a booster immunization against tetanus and diphtheria every 10 years. Additionally, pregnant women should get immunized with the Tdap vaccination every 27 to 36 weeks of pregnancy.

Will Rise in Government Initiatives Focusing on Prevention of Diseases Drive the Growth of the Adult Vaccines Market?

The global adult vaccinations market is on track for significant development, driven by an increasing number of government efforts aimed at preventing certain diseases and epidemics. Governments around the world are recognizing the importance of vaccination in protecting public health, particularly among adults. As a result countries are implementing a variety of programs and policies to promote adult vaccination, ranging from public awareness campaigns to vaccine mandates in certain industries such as healthcare and tourism.

The growing number of government attempts to avoid specific diseases and epidemics is predicted to drive the worldwide adult vaccines market. According to the National Health Mission, India is committed to the aim of eliminating measles and controlling rubella, hence the Measles Rubella (MR) vaccine was introduced in the country through a phased campaign in 2017. The Measles-Rubella (MR) campaign aims to immunize around 4.1 million children aged 9 months to 15 years with two doses administered at 9-12 months and 16-24 months. The rubella component is now routinely administered as part of the MR vaccination.

Overall, the growth of the global adult vaccines market in the coming years and government-coordinated efforts to encourage adult immunization are projected to drive. By prioritizing vaccination as a cornerstone of public health policy, governments hope to minimize the burden of vaccine-preventable diseases, boost population immunity and protect the health and well-being of adults worldwide.

How will Lack of Awareness among the Rural Areas or Remote Areas Impact Adult Vaccine Market?

The expansion of the global adult vaccination sector may encounter considerable challenges due to a limited understanding of the benefits of adult vaccination particularly in developing countries. This lack of awareness affects not only emerging nations but also isolated and rural communities where access to healthcare information and services is frequently limited. Individuals who do not understand the necessity of adult vaccination may not seek out or prioritize receiving recommended vaccines limiting market growth.

Furthermore, the initial expenses associated with adult immunizations can be a barrier to expansion, especially in places where healthcare funds are limited. In addition to financial hurdles, logistical issues create implementation barriers that hamper the growth of the worldwide adult vaccines sector. The lack of effective reminder mechanisms to encourage people to be vaccinated can lead to missed opportunities for immunization.

The global adult vaccines industry's development potential by raising awareness, lowering prices, and streamlining vaccine delivery systems, stakeholders can help promote and develop the potential to enable greater access to preventive healthcare for adults globally.

Category-Wise Acumens

How the Adult Vaccine Market is divided into Categories based on Specific Disease of Vaccine Targets?

The worldwide adult vaccinations market is divided according to the specific disease that the vaccine addresses. These include varicella (chickenpox), influenza, human papillomavirus (HPV), tetanus, measles, shingles, pneumococcal illness, and others.

Among them, the influenza vaccine category is currently leading, accounting for over 55% of the global market share in 2022. This dominance is projected to continue, with estimates showing the fastest growth rate for this segment in the future years. The broad prevalence of seasonal flu, an acute respiratory illness caused by the influenza virus is a major driver of the demand for adult vaccine .

According to the World Health Organization (WHO), seasonal flu causes over 400,000 fatalities each year, largely owing to respiratory problems. Furthermore, WHO data show that influenza is especially hazardous for persons over 60 in developed countries, underscoring the importance of broad immunization in this age range.

How the Incising Prevalence of Bacterial and Viral Infection will Drive the Multivalent Vaccines Segments?

The global adult vaccinations industry is divided into two sectors based on the type of vaccine used monovalent and multivalent. Particularly, in 2022, the multivalent vaccines segment contributed significantly to the global market share. According to projections, this segment's influence in the market will grow even stronger in the next years. This expected growth over the evaluation period can be linked to a significant increase in bacterial and viral infections found in Asian and Latin American countries, among others, around the world.

The division of the adult vaccinations market into monovalent and multivalent categories highlights the wide range of vaccines available to treat numerous infectious diseases in adults. In recent years, the multivalent vaccines category has emerged as a key driver of industry growth, thanks to its capacity to defend against several infections with a single vaccination formulation. This immunization efficiency is especially beneficial in areas with increased rates of both bacterial and viral illnesses.

Overall, the trajectory of the multivalent vaccines segment's growth in the worldwide adult vaccines business emphasizes the necessity of innovation and adaptation in dealing with changing healthcare concerns. Multivalent vaccinations, which provide broad-spectrum protection against many pathogens, have the potential to play a critical role in advancing public health goals and lowering the global burden of infectious illnesses.

Country/Region-wise Acumens

How does the North America Account for Major Share in Adult Vaccine Market over the Analysis?

The North American region, which commanded a significant 60% share of the worldwide adult vaccines market in 2022, is expected to maintain its dominance in terms of market revenue share between 2023 and 2030. This expected ongoing leadership in the global market can be linked to an increase in the frequency of viral infections among adults particularly in Canada and the United States.

The North American market is predicted to rise significantly due to an increase in viral infections among adults underscoring the importance of vaccination in disease prevention and public health risk reduction. Particularly, the National Institutes of Health (NIH) found that the influenza vaccine alone reduces approximately 90,000 hospitalizations among older persons in the United States each year, emphasizing the relevance of immunization in reducing healthcare expenses.

The US Centers for Disease Control and Prevention (CDC) has published recommendations for adults to get vaccinated against numerous diseases on a regular basis. Tetanus, diphtheria, and pertussis (Tdap) vaccinations, as well as seasonal influenza, are recommended for all adults. The CDC also advises herpes zoster vaccine for people over the age of 50 and pneumococcal vaccination for adults 65 and older.

How Does the European Market Experience Significant Growth in Adult Vaccine Market?

The European adult vaccine industry is predicted to develop significantly, driven by broad immunization recommendations from EU member states. Notably, as of January 2022, roughly 29 out of 30 EU nations had approved influenza vaccination, demonstrating a strong commitment to preventive healthcare measures. Furthermore, 21 EU nations suggest immunization for pneumonia, demonstrating the importance of protecting adults against respiratory illnesses.

These comprehensive vaccination guidelines from EU countries represent a concerted effort to promote adult immunization and prevent vaccine-preventable diseases. By campaigning for immunization against a variety of infectious agents, European countries are taking proactive actions to protect public health and minimize the burden of preventable illnesses in adults.

As EU countries emphasize immunization efforts and increase access to adult vaccines, the region is positioned to become a leading market for adult vaccination, benefiting both individuals and healthcare systems.

Competitive Landscape

The adult vaccine market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the adult vaccine market include:

• Solvay Pharmaceuticals
• Moderna
• BioCSL (Seqirus)
• Aventis Pasteur
• Sanofi Pasteur
• Pfizer Inc.
• Merck & Co. Inc.
• GlaxoSmithKline Plc
• Novartis AG
• Johnson & Johnson
• BioNTech
• Bharat Biotech International Limited
• Zhifei
• Wyeth Vaccines
• AstraZeneca Plc
• Medimmune
• Sinovac
• Baxter International Healthcare Company
• Chiron Vaccines
• Serum Institute of India

Latest Developments

• In August 2022, the WHO Strategic Advisory Group of Experts on Immunization (SAGE) released interim recommendations for the use of the Pfizer BioNTech (BNT162b2) vaccine against COVID-19. This post summarizes those interim suggestions; you can find the complete advice document here. According to SAGE, the Pfizer-BioNTech COVID-19 mRNA vaccine is both safe and efficacious.
• In August 2020, Novavax and Serum Institute of India inked a license agreement for the manufacturing and sale of their innovative COVID-19 vaccine candidate, NVX-CoV2373, in low- and middle-income countries, including India. This would improve the company's revenue.

Adult Vaccine Market, By Category

• Vaccine:
• Varicella
• Influenza
• Human Papillomavirus
• Tetanus
• Measles
• Zoster
• Pneumococcal
• Vaccine Type:
• Monovalent Vaccines
• Multivalent Vaccines
• Technology:
• Live Attenuated Vaccines
• Inactivated Viral/Bacterial Vaccines
• Toxoid Vaccines
• Recombinant Vaccines
• Conjugate Vaccines
• End-User:
• Private Healthcare Firms
• Government Hospitals
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL ADULT VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL ADULT VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porter's Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL ADULT VACCINE MARKET, BY VACCINE

• 5.1 Overview
• 5.2 Hepatitis
• 5.3 Human Papillomavirus
• 5.4 Influenza
• 5.5 Zoster
• 5.6 Others

6 GLOBAL ADULT VACCINE MARKET, BY VACCINE-TYPE

• 6.1 Overview
• 6.2 Monovalent vaccines
• 6.3 Multivalent vaccines

7 GLOBAL ADULT VACCINE MARKET, BY TECHNOLOGY

• 7.1 Overview
• 7.2 Live Attenuated Vaccines
• 7.3 Inactivated Viral/Bacterial Vaccines
• 7.4 Toxoid Vaccines
• 7.5 Recombinant Vaccines
• 7.6 Conjugate Vaccines

8 GLOBAL ADULT VACCINE MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 The U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 The U.K.
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Argentina
  • 8.5.3 Rest of LATAM
• 8.6 Middle East and Africa
  • 8.6.1 UAE
  • 8.6.2 Saudi Arabia
  • 8.6.3 South Africa
  • 8.6.4 Rest of the Middle East and Africa

9 GLOBAL ADULT VACCINE MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Pfizer, Inc.
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 GlaxoSmithKline Plc.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Sanofi Pasteur
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Merck & Co.
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 CSL Limited
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Johnson & Johnson
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Medimmune
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Serum Institute of India
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 AstraZeneca Plc
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Novartis
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

Related Research